AN DER GOLDGRUBE 12, MAINZ, 2M
Disclosure of Share Buyback Program Pursuant to Art. 5(1) Lit. A) of the Regulation (EU) No. 596/2014 and Art. 2(1) of the Delegated Regulation (EU) 2016/1052
Global Data for and’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
To Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
Voting Results - Overview Ordinary Annual General Meeting on 15/05/2026
Announces New ADS Repurchase Program
First Quarter 2026 Financial Results & Corporate Update
Reports Development Update and Financial Results for Q1 2026
Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Tender Offer Statement by Third Party
No filings found
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Tender Offer Statement by Third Party
Amended Notice of Proposed Sale of Securities
S-8 POS